文献速递炎症性肠病

克罗恩病中英夫利西单抗与阿达木单抗药物谷浓度:与疾病活动度的不同关联及影响因素

Infliximab and adalimumab drug levels in Crohn's disease: contrasting associations with disease activity and influencing factors.
PubMed 文献 · Aliment Pharmacol Ther · 2017-05-08

该横断面服务评估纳入191例接受维持治疗的克罗恩病患者(英夫利西单抗96例、阿达木单抗95例),英夫利西单抗谷浓度与临床缓解(P=.081)、生化缓解(P=.003)及粪钙卫蛋白正常化(P<.0001)相关,ROC分析阈值分别为1.5、3.4和5.7 μg/mL;阿达木单抗浓度在各终点下活动期与缓解期相似,无此类关联。

要点

  • 英夫利西单抗谷浓度与临床缓解(P=.081)、生化缓解(P=.003)及粪钙卫蛋白正常化(P<.0001)相关,ROC阈值分别为1.5、3.4、5.7 μg/mL。
  • 阿达木单抗浓度无论采用何种终点,活动期与缓解期均相似,未显示与疾病活动度的关联。
  • 英夫利西单抗剂量、体重指数和结肠病变独立解释31%的浓度变异;每周给药、白蛋白和体重解释阿达木单抗浓度变异的23%。

核心结论

  • 英夫利西单抗药物浓度与克罗恩病缓解深度/缓解相关,而阿达木单抗未观察到这种关系。
  • 需要更多数据来解释药物浓度的变异。

研究设计与样本

  • 横断面服务评估,纳入接受英夫利西单抗或阿达木单抗维持治疗的克罗恩病患者191例(英夫利西单抗96例、阿达木单抗95例)。
  • 英夫利西单抗测定谷浓度,阿达木单抗于任意时间点测定浓度;终点包括Harvey-Bradshaw指数、C反应蛋白和粪钙卫蛋白。
  • 对接受硫嘌呤治疗的患者测定了6-硫鸟嘌呤核苷酸(TGN)浓度。

主要发现

  • 英夫利西单抗浓度在临床缓解(P=.081)、生化缓解(P=.003)和粪钙卫蛋白正常化(P<.0001)方面存在差异,ROC分析相应阈值分别为1.5、3.4和5.7 μg/mL。
  • 阿达木单抗浓度在所有评估终点下活动期与缓解期相似。
  • 模型显示较高英夫利西单抗剂量、体重指数和结肠病变独立解释英夫利西单抗浓度变异的31%。
  • 每周给药、白蛋白和体重解释阿达木单抗浓度变异的23%。
  • TGN浓度与药物浓度不相关。

关键数值与推荐

  • 英夫利西单抗临床缓解阈值为1.5 μg/mL(ROC分析)。
  • 英夫利西单抗生化缓解阈值为3.4 μg/mL(ROC分析)。
  • 英夫利西单抗粪钙卫蛋白正常化阈值为5.7 μg/mL(ROC分析)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 需要更多数据来解释药物浓度的变异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Discriminative drug level thresholds for disease activity endpoints in patients with Crohn's disease. have been consistently demonstrated with infliximab, but not adalimumab. AIMS: To identify threshold concentrations for infliximab and adalimumab in Crohn's disease according to different disease endpoints, and factors that influence drug levels. METHODS: We performed a cross-sectional service evaluation of patients receiving maintenance infliximab or adalimumab for Crohn's disease. Serum drug levels were at trough for infliximab and at any time point for adalimumab. Endpoints included Harvey-Bradshaw index, C-reactive protein and faecal calprotectin. 6-tioguanine nucleotide (TGN) concentrations were measured in patients treated with thiopurines. RESULTS: A total of 191 patients (96 infliximab, 95 adalimumab) were included. Differences in infliximab levels were observed for clinical (P=.081) and biochemical remission (P=.003) and faecal calprotectin normalisation (P<.0001) with corresponding thresholds identified on ROC analysis of 1.5, 3.4 and 5.7 μg/mL. Adalimumab levels were similar between active disease and remission regardless of the endpoint assessed. Modelling identified that higher infliximab dose, body mass index and colonic disease independently accounted for 31% of the variation in infliximab levels, and weekly dosing, albumin and weight accounted for 23% of variation in adalimumab levels. TGN levels did not correlate with drug levels. CONCLUSIONS: Infliximab drug levels are associated with the depth of response/remission in patients with Crohn's disease, but no such relationship was observed for adalimumab. More data are needed to explain the variation in drug levels.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Ward MG, Warner B, Unsworth N, et al. Infliximab and adalimumab drug levels in Crohn's disease: contrasting associations with disease activity and influencing factors. Aliment Pharmacol Ther. 2017. PMID: 28481014. doi:10.1111/apt.14124

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。